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Abstract
Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is defined as a sudden acceleration of the disease
with the appearance of pulmonary infiltrates superimposed on the characteristic pattern of IPF that leads to a
significant decline in lung function. It has high in-hospital mortality rates, despite medical treatment with
systematic steroids. We sought to investigate whether there were in-hospital mortality differences
according to clinical stratification (AE, suspected AE, or AE of known cause) and/or treatment with
systemic steroids. We reviewed the clinical characteristics and outcomes of patients with IPF admitted to
our hospital during the years 2003–2014 due to a worsening of their clinical status. We identified 50 IPF
patients, 9 with AE (18%), 12 with suspected exacerbation (24%), and 29 with AE of known cause (58%), mostly
respiratory infections. In-hospital mortality was similar in the three groups (33% vs. 17% vs. 34%, respectively).
Likewise, we did not find differences between them with respect to the use of systemic steroids (length of
treatment duration or total dose). Nevertheless, there was an independent association between in-hospital
mortality and high average daily steroid dose. We did not observe significant differences in prognosis or use of
systemic steroids according to current diagnostic stratification groups in patients hospitalized because of an
exacerbation of IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive
disease with an estimated prevalence of 13–20 cases/
100,000 inhabitants1 and a high in-hospital mortality
rate (50% at 5 years after the diagnosis).2 Exacerba-
tions of IPF can occur at any stage during the evolu-
tion of the disease, have an incidence of 5–10% per
year, and are associated with an in-hospital mortality
rate that ranges between 50% and 80%.3,4
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Because the biological mechanisms underlying IPF
exacerbations are unknown, there are no specific
diagnostic biomarkers. In 2007, a consensus state-
ment proposed the following diagnostic criteria for
IPF exacerbations: (1) a previous or concurrent diag-
nosis of IPF; (2) unexplained worsening of dyspnea
within the past 30 days; (3) high-resolution computed
tomography (HRCT) showing the appearance of new
pulmonary infiltrates in addition to usual interstitial
pneumonia (UIP) radiological pattern, in the absence
of lung infections or alternative causes of clinical
deterioration; and (4) exclusion of alternative causes,
including pulmonary infection by endotracheal aspi-
rate or bronchoalveolar lavage. Yet, because in clin-
ical practice these criteria are sometimes difficult to
fulfill, some experts proposed an alternative diagnos-
tic category (suspected acute exacerbation (SAE)) for
those patients who do not meet all four criteria, but in
whom no other known cause could be established.
This definition was in fact tested in a cohort of
patients from the Sildenafil Trial of Exercise Perfor-
mance in Idiopathic Pulmonary Fibrosis (STEP-IPF)
clinical trial, and it was observed that patients with
SAE were clinically indistinguishable from those with
a definitive diagnosis of acute exacerbation (AE) of
IPF.5 Recently, an international working group
report6 has proposed a new definition where
“etiology” is no longer requested among these criteria
in the diagnosis, so there may be AE of known etiol-
ogy (AEKE). The applicability and impact of these
new definitions have not yet been tested in a “real”
clinical setting.
High doses of systemic corticosteroids is the rec-
ommended treatment for AEs of IPF.2 Yet this rec-
ommendation is not based on any randomized clinical
trials.2,3 Furthermore, given that corticosteroids
increase in-hospital mortality in stable IPF patients,7
the treatment has been criticized.8
This study sought to: (1) compare the clinical char-
acteristics and in-hospital mortality rates of hospita-
lized patients with AE, SAE, or AEKE and (2)
investigate potential differential effects of systemic
steroid treatment in these three groups of IPF patients.
Materials and methods
Study design and ethics
This is a retrospective, observational, uncontrolled
analysis of electronic medical records (EMR) of
patients hospitalized in the Hospital Clinic (Barcelona,
Spain) due to exacerbation of IPF (see diagnostic
criteria below). This analysis was approved by the
Ethics Committee of our institution.
Population studied
Patients were identified by reviewing the discharge
EMRs of our hospital from 2003 until 2014 using
three different International Classification of Dis-
eases (ICD) codes for IPF: 515 (post-inflammatory
pulmonary fibrosis), 516.3 (idiopathic interstitial
pneumonia), and 516.8 (alveolar lung disease or
other interstitial pneumonia). Patients with planned
hospital admissions were excluded from analysis.
Likewise, patients with an active malignant neo-
plasm at admission, HIV infection, severe immu-
nosuppression resulting from bone marrow
transplantation or solid organ transplant, and severe
hematological diseases were also excluded. HRCT
scans and lung pathology samples were reviewed
by the authors, and diagnosis of IPF was confirmed
following the multidisciplinary international guide-
lines of IPF.2
Patient stratification
On the basis of clinical information, HRCT findings,
pathological diagnosis, and following multidisci-
plinary consensus, patients were stratified in three
groups3,5: (1) AE (previous or concurrent diagnosis
of IPF, unexplained worsening dyspnea within
30 days prior to admission, and the appearance of
new pulmonary infiltrates added to UIP radiological
pattern with the absence of lung infections or alter-
native causes of clinical deterioration of the patient
condition), (2) SAE (worsening or unexplained dys-
pnea within 30 days prior to admission but without
the fulfillment of all the criteria of AE), and (3)
AEKE (appearance or worsening of dyspnea within
30 days prior to admission that is associated to an
identified cause of deterioration (respiratory infec-
tion, heart failure, and pulmonary embolism). Lower
respiratory infection was defined as patients who
presented fever, cough, and sputum with purulent
characteristics and/or a positive respiratory micro-
biological culture during the first 48 hours of admis-
sion. Based on the clinical condition that hampered
the performance of the fibrobronchoscopy in
patients, the procedure was only performed in 2 of
the 50 patients; therefore, it is possible that the pro-
portion of exacerbation due to infectious disease
could be underestimated in the study.
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Measurements
Relevant clinical, physiological, and biochemical data
were collected and analyzed from the EMR of all
included patients.
Statistical analysis
Categorical variables were summarized by total num-
ber and percentages, whereas in continuous variables
we first performed a Kolmogorov test, those of them
which followed a normal distribution were summar-
ized by their mean and standard deviation, while those
of them that did not meet this condition were
expressed by their median and percentiles.
Continuous variables were compared across
different groups using one-way analysis of variance,
with Tukey’s post hoc comparisons. In the case of
continuous variables which did not follow a normal
distribution, we used a nonparametric test (Mann–
Whitney U). Categorical variables were contrasted
using the w2 test or Fisher’s exact tests.
To rule out factors that could affect the association
between in-hospital mortality and corticosteroids
dose, a multivariate logistic regression analysis was
performed (conditional stepwise forward model,
pin < 0.10, pout < 0.05), the results being adjusted for
the following variables: age, gender, forced vital
capacity (FVC), pulmonary gas exchange (PaFiO2)
before exacerbation, average daily dose of corticos-
teroids, and antibiotic therapy received during the
patients hospital stay.
In-hospital mortality was analyzed during the hos-
pital stay and 1 year after discharge. Receiver oper-
ating characteristics (ROC) curves were used to
determine the optimal cutoff values of daily corti-
costeroids dose in relation to in-hospital mortality.
Multivariate analyses of 1-year survival were per-
formed with Cox proportional hazard regression. A
conditional stepwise forward model (pin < 0.10, pout
< 0.05) was used to correct for colinearity, and
adjusted odds ratios and 95% confidence intervals
were computed for variables independently associ-
ated with these events in all multivariate analyses.
The value of p < 0.05 was considered statistically
significant.
Results
Figure 1 presents the consort diagram of the study.
We finally included in the analysis a total of 50
patients, 9 of whom had AE (18%), 12 SAE (24%),
and 29 AEKE (58%). In the latter group, 28 patients
(48%) fulfilled the criteria for respiratory infection
as the cause of the acute episode. In these patients,
cultures were positive in only four cases (two spu-
tum, one broncoaspirate, and one blood), with the
following microbiological results: Mycobacterirum
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Figure 1. Schematic representation of the studied population. The main reasons for excluding patients were planned
hospital admission without worsening of the respiratory symptoms (n ¼ 21), patients with severe immunosuppression
resulting from bone marrow transplantation or solid organ transplant (n ¼ 2), severe hematological diseases (n ¼ 6), and
active malign neoplasm (n ¼ 5). ICD: International Classification of Diseases.
Cuerpo et al. 3
tuberculosis, Pseudomonas aeruginosa, Candida
spp., Streptococcus hominis. In one patient cardiac
failure was the established cause of AEKE.
We did not find any significant difference between
groups in relation to their clinical characteristics
(Table 1), hospital admission-related data (Table 2),
outcomes (Table 3), or 1-year survival (Figure 2),
except for the fact that the number of days with
respiratory symptoms before hospitalization as well
as antibiotics use was higher in patients with AEKE
(Table 2).
Role of corticosteroid treatment
There were no significant differences between
groups with regard to the use of corticosteroids,
length of treatment, total dose, or daily average
dose (Table 2). However, we observed (Table 4)
that higher doses of corticosteroids received during
hospitalization were associated with higher in-
hospital mortality (odds ratio (OR) 1.044, 95% con-
fidence interval (CI; 1.006–1.085), p ¼ 0.024).
ROC curve of daily corticosteroids dose in relation
to in-hospital mortality was performed (Figure
3(a)). A daily corticosteroid dose 55 mg/day had
the best discriminative capacity to predict hospital
survival. Interestingly, 1 year in-hospital mortality
was also higher in patients who received a daily
corticosteroid dose of 55 mg/day or higher while
in hospital (Figure 3(b)). Likewise, Cox regression
analysis identified an association between 1-year
in-hospital mortality and hospital daily corticoster-
oid dose (OR 1.075, 95% CI (1.044–1.107), p <
0.001).
Conclusions and discussion
The main observations of this study are the following:
(1) contrary to previous consensus recommenda-
tions,3 we could not identify clinically relevant differ-
ences between AE, SAE, and AEKE and (2) there is
a relationship between higher doses of systemic
steroids and both during admission and 1-year
in-hospital mortality.
Previous studies and interpretation of findings
Our results, in a real-world setting, showed that the
relative proportion of the combined group of AE and
SAE (as well as in-hospital mortality, Figure 2) was
similar to that reported in the analysis of the STEP-
IPF clinical trial (42% in our group vs. 51% of the
STEP-IPF trial).9 The percentage of survival was
Table 1. Baseline characteristics of patients (n ¼ 50).
AE (n ¼ 9) SAE (n ¼ 12) AEKE (n ¼ 29)
Age (years), mean + SD 77 + 10 75 + 9 74 + 11
Gender female/male, n 4/5 4/8 8/21
Smoking status, n (%)
Never smoker 4 (44) 3 (25) 12 (41)
Ex-smoker 5 (56) 9 (75) 16 (56)
Current smoker 0 (0) 0 (0) 1 (3)
Underlying diseases, n (%)
Diabetes mellitus 2 (22) 2 (17) 6 (21)
Liver disease 0 (0) 1 (8) 3 (10)
Chronic heart disordersa 3 (33) 5 (42) 13 (45)
PFT nearest to hospitalization, mean + SD
FVC % predicted 59 + 23 50 + 13 56 + 20
DLCO % predicted 45 + 7 32 + 9 38 + 15
Arterial blood gases nearest to hospitalization, mean + SD
PaO2 (mmHg) 67 + 14 66 + 12 64 + 14
PaCO2 (mmHg) 39 + 4 37 + 4 38 + 5
IPF drug therapy before hospitalization, n (%)
Corticosteroids 5 (56) 8 (67) 22 (76)
Immunosuppression therapy 3 (33) 3 (25) 10 (34)
IPF: idiopathic pulmonary fibrosis; PFT: pulmonary function test; FVC: forced vital capacity; DLCO: lung diffusing capacity for carbon
monoxide; AE: acute exacerbation; SAE: suspected acute exacerbation; AEKE: acute exacerbation of known etiology.
aChronic heart disorders include coronary artery disease, hypertensive or valvular heart diseases, and dilated myocardial disease
of any cause.
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also similar compared to the study of Song et al.4
(50% survival with steroid pulses þ cytotoxic agent
and 53% with steroid pulses alone) compared to our
group. These observations raise questions concern-
ing the clinical usefulness of the “old”
classification.3
High doses of systemic corticosteroids are recom-
mended and often prescribed in clinical practice for
patients with AE of IPF, despite the fact that only a
few uncontrolled studies have explored their
impact.10–14 It is noteworthy that, so far, none of them
investigated its potential effect on prognosis. These
recommendations have been criticized6,8 because,
first, corticosteroids are not recommended in stable
IPF, where they can even increase in-hospital mortal-
ity2 and, second, because diffuse alveolar damage
Table 2. Hospitalization characteristics (n ¼ 50).
AE (n ¼ 9) SAE (n ¼ 12) AEKE (n ¼ 29)
Days of previous respiratory symptoms before hospitalization, mean+ SD 17 + 7 19 + 16 9 + 9
Arterial blood gases on admission, mean + SD
PaO2 (mmHg) 63 + 13 68 + 23 73 + 23
PaO2/FiO2 270 + 50 239 + 71 258 + 88
Laboratory data on admission, mean + SD
C-reactive protein (mg/dL) 5.70 + 3.10 3.10 + 3.81 8.13 + 7.56
White blood cell count  109/L 9.62 + 2.88 10.84 + 3.58 11.42 + 4.93
Bronchoscopy performed, n (%) 0 (0) 0 (0) 2 (7)
Drug therapy during hospitalization, n (%)
Corticosteroids 8 (89) 12 (100) 27 (93)
Length of treatment (days), mean + SD 5 + 3 7 + 4 7 + 5
Total dose (mg), mean + SD 237 + 141 355 + 202 289 + 307
Average daily dose (mg/day), mean + SD 47 + 17 49 + 13 40 + 24
Antibiotics, n (%)
None 7 (78) 10 (83) 2 (7)
Amoxicillin 0 (0) 1 (8) 2 (7)
Ciprofloxacin 0 (0) 0 (0) 1 (3)
Levofloxacin 2 (22) 0 (0) 14 (48)
Ceftriaxone þ azithromycin 0 (0) 1 (8) 9 (31)
Tuberculosis treatment 0 (0) 0 (0) 1 (3)
Mechanical ventilation, n (%)
None 9 (100) 11 (92) 26 (90)
NIV 0 (0) 1 (8) 2 (7)
Invasive MV 0 (0) 0 (0) 1 (3)
NIV: noninvasive ventilation; MV: mechanical ventilation; AE: acute exacerbation; SAE: suspected acute exacerbation; AEKE: acute
exacerbation of known etiology.






(n ¼ 29) p Valuea p Valueb
Months from IPF diagnosis to first hospitalization, median (range) 20 (5–67) 13 (3–44) 20 (5–49) 0.59 0.91
Hospitalization days, median (range) 4 (3–8) 7 (4–10) 6 (3–8) 0.78 0.90
Oxygen therapy at discharge, n (%) 4 (44) 9 (75) 19 (65) 0.34 >0.99
Palliative care at discharge, n (%) 1 (11) 5 (42) 8 (28) 0.30 >0.99
Hospital mortality, n (%) 3 (33) 2 (17) 10 (34) 0.51 0.62
New hospitalizations after 6 months from discharge, n (%) 3 (33) 5 (42) 12 (41) > 0.99 >0.99
AE: acute exacerbation; SAE: suspected acute exacerbation; AEKE: acute exacerbation of known etiology; IPF: idiopathic pulmonary
fibrosis.
aComparisons between the three groups of the study.
bComparisons between idiopathic and suspected idiopathic acute exacerbations versus acute exacerbations of known cause.
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(DAD) is the usual histological substrate of AE of IPF
6 and corticosteroids have proved ineffective in acute
lung injury, also characterized by DAD.8,15 In con-
cordance with our study, in a recent observational
study, patients treated previously to an AE of IPF with
corticosteroids have a worst prognosis.16 Our results
lend support to the conclusion that systemic corticos-
teroids may be ineffective in the treatment of IPF
exacerbation. In fact, despite being a relatively small
size study, we observed that those patients who
received higher dose of corticosteroids had higher
in-hospital mortality and 1 year mortality after dis-
charge from hospital (Figure 3). Of course, these find-
ings may simply indicate bias by indication, since
higher doses of steroids are likely to have been used
in more severely ill patients; however, in the multi-
variate analysis, we corrected the results for the pos-
sible variables that might have influenced the
Figure 2. Survival analysis for the three definition groups. (a) Survival analysis comparing AE, SAE and AEKE (b) Survival
analysis comparing idiopathic excerbation (combined AE/SAE patients) and AEKE. AE: acute exacerbation; SAE: suspected
acute exacerbation; AEKE: acute exacerbation of known etiology.
Table 4. Association between corticosteroids dose and in-hospital mortality.
Dead Alive p Value
Average daily dose (mg/day), median (25th–75th percentile) 60 (52.5–60) 40 (25–55) 0.010
Length of treatment (days), mean+ SD 5.78+ 4.33 7.30+ 4.90 0.32
Total corticosteroid dose (mg), median (25th–75th percentile) 280 (110–450) 240 (9.5–410) 0.584
Figure 3. (a) ROC curves of daily corticosteroids dose in relation to in-hospital mortality and (b) survival analysis
between patients with high and low doses of corticosteroids. ROC: receiver operating characteristics.
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outcomes such as age, gender, and respiratory func-
tion (FVC and PaFiO2).
Potential limitations
Our study has several clear limitations, most notably its
retrospective, descriptive, and uncontrolled design.
However, to the best of our knowledge, it is the first
to explore the potential clinical relevance of the
recently suggested patient stratification (AE, SAE, and
AEKE), as well as the potential effects of systemic
steroid treatment in both in-hospital and 1-year after
discharge from hospital mortality. Likewise, our study
represents the experience of a single center and has
therefore a relatively small sample size. Nevertheless,
our center is a national reference in intensive and spe-
cialized respiratory care of interstitial lung diseases,17–
20 so these results represent state-ofthe-art management
of acute IPF exacerbation during the last 10 years.
Conclusions
Our results indicate that (1) the clinical stratification
of patients in AE, SAE, and AEKE does not really
identify different patient subpopulations and (2)
intensive systemic steroid treatment is associated with
higher in-hospital and 1-year after discharge from
hospital mortality. Until novel and more specific
therapies are developed and tested rigorously, our
results suggest that the daily dose of prednisone in
these patients should be carefully monitored during
AE of IPF.
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